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Aims The most effective regimen for the prevention of contrast-induced nephropathy (CIN) remains uncertain. Our
purpose was to compare two regimens of sodium bicarbonate with 24 h sodium chloride 0.9% infusion in the pre-
vention of CIN.
Methods
and results
We performed a prospective, randomized trial between March 2005 and December 2009, including 258 consecutive
patients with renal insufficiency undergoing intravascular contrast procedures. Patients were randomized to receive
intravenous volume supplementation with either (A) sodium chloride 0.9% 1 mL/kg/h for at least 12 h prior and after
the procedure or (B) sodium bicarbonate (166 mEq/L) 3 mL/kg for 1 h before and 1 mL/kg/h for 6 h after the pro-
cedure or (C) sodium bicarbonate (166 mEq/L) 3 mL/kg over 20 min before the procedure plus sodium bicarbonate
orally (500 mg per 10 kg). The primary endpoint was the change in estimated glomerular filtration rate (eGFR) within
48 h after contrast. Secondary endpoints included the development of CIN. The maximum change in eGFR was sig-
nificantly greater in Group B compared with Group A {mean difference 23.9 [95% confidence interval (CI), 26.8 to
21] mL/min/1.73 m2, P ¼ 0.009} and similar between Groups C and B [mean difference 1.3 (95% CI, 21.7–4.3)
mL/min/1.73 m2, P ¼ 0.39]. The incidence of CIN was significantly lower in Group A (1%) vs. Group B
(9%, P ¼ 0.02) and similar between Groups B and C (10%, P ¼ 0.9).
Conclusion Volume supplementation with 24 h sodium chloride 0.9% is superior to sodium bicarbonate for the prevention of
CIN. A short-term regimen with sodium bicarbonate is non-inferior to a 7 h regimen.
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Introduction
Acute deterioration in renal function caused by radiographic con-
trast agents is generally mild and transient but can result in lasting
renal dysfunction and the need for renal replacement therapy.
Contrast-induced nephropathy (CIN) is a leading cause of new-
onset renal failure in hospitalized patients, with the highest risk
observed in patients with pre-existing impaired renal function.1,2
It is associated with significantly increased in-hospital and long-
term morbidity and mortality, acceleration of chronic renal
disease, and increased costs of medical care.3
Since there is no specific therapy of CIN and the disease is iat-
rogenic, prevention is of paramount importance. The
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pathophysiology of CIN is poorly understood but may include
acute vasoconstriction resulting in renal hypoperfusion,
hypoxia-induced oxidative stress, and free radicals generated
within the acid environment of the renal medulla.4,5 Varieties of
approaches have been suggested for the prevention of CIN with
target on these pathomechanisms.6–11 Twenty-four hour volume
supplementation with sodium chloride 0.9% is uniformly accepted
and used in clinical practice for prevention and can be considered a
cornerstone in the prevention of CIN.12,13
Recently, studies have begun to evaluate whether volume sup-
plementation with sodium bicarbonate may be superior to
volume supplementation with sodium chloride 0.9%. Based on
the hypothesis that alkalinizing renal tubular fluid with bicarbonate
may reduce renal injury, Merten et al.14 presented a 7 h sodium bi-
carbonate regimen that appeared to be superior to a 7 h sodium
chloride 0.9% regimen. The strategy of 24 h volume supplementa-
tion with sodium chloride 0.9%, supporting the hypothesis that the
extent of volume supplementation per se is the most effective
mechanism, has never been directly compared with the strategy
of alkalinization.
In addition, it is unknown whether the administration of a similar
amount of sodium bicarbonate as a short-term (e.g. 20 min)
regimen including intravenous and oral sodium bicarbonate may
be as effective as the 7 h intravenous approach.15 For obvious lo-
gistic reasons, the short-term regimen would be highly attractive in
clinical practice including outpatient procedures.
Methods
Study design
In this multicentre (three centres), randomized, open-label, controlled
trial, we compared three different prevention procedures of CIN.
Study patients
All patients admitted with renal dysfunction {actual serum creatinine
level above the upper limit of normal of the serum creatinine
(.93 mmol/L for women and .117 mmol/L for men) or estimated
glomerular filtration rate (eGFR) ,60 mL/min/1.73 m2 [eGFR calcu-
lated using the abbreviated Modification of Diet in Renal Disease
(MDRD) study equation16]} scheduled to undergo an intra-arterial
or intravenous radiographic contrast procedure on the next day
were screened.
This study was conducted according to the principles of the revised
Declaration of Helsinki and good clinical practice guidelines and was
approved by the local Ethics Committees. All patients gave written
informed consent before study entry.
Renal insufficiency was defined as a decrease in GFR and since the
GFR has to be reduced by 50% before a rise in serum creatinine
occurs, an elevated serum creatinine level was used as the cut-off
point for the definition for renal dysfunction.17
Exclusion criteria were age ,18 years, pre-existing dialysis, allergy
to radiographic contrast, pregnancy, severe heart failure (NYHA func-
tional class III and IV), N-acetylcysteine ≤24 h before contrast, and
clinical condition requiring continuous fluid therapy, e.g. severe
sepsis. Gold standard diagnosis of heart failure was built on the basis
of all available medical records pertaining to the individual patient,
on history, clinical presentation, and standard investigations, including
natriuretic peptides and echocardiography (according to the current
guidelines for heart failure of the European society of cardiology).18
Laboratory measures
Serum creatinine was measured with the enzymatic method in two
centres (Centre 1: COBAS INTEGRAw, Roche Diagnostics GmbH, at
378C, calibrated to IDMS standard; Centre 2: Wako Chemicals GmbH,
at 378C, calibrated to NIST-Standard SRM914a) and with the Jaffe
method in the third centre [Olympus AU640w, at 378C, modified Jaffe
method (kinetic alkaline picrate)]. Cystatin C of all patients of the
three centres was measured in a core laboratory in the University Hos-
pital of Basel (nephelometry, Dako; IMMAGEw 800, Beckman Coulter).
Procedures
Patients were randomized to one of the three regimens of volume sup-
plementation described below. Randomization with stratification for
intra-arterial and intravenous radiographic contrast procedures and
for each participating institution was performed by using sealed envel-
opes, 1:1:1 to each group.19 The analysis was performed according to
the intent-to-treat principle.
(A) 24 h sodium chloride 0.9%
The infusion of 0.9% sodium chloride was administered at a continuous
rate of 1 mL/kg/h,20 beginning from 8 p.m. on the day before the pro-
cedure and for at least 12 h after the procedure.
(B) 7 h sodium bicarbonate
The initial intravenous bolus was 3 mL/kg/h of 166 mEq/L sodium bi-
carbonate for 1 h immediately before radiocontrast injection. Follow-
ing this, patients received the same fluid at a rate of 1 mL/kg/h
during the contrast exposure and for 6 h after the procedure.14
(C) Short-term sodium bicarbonate
Patients received sodium bicarbonate 166 mEq/L as a bolus (3 mL/kg;
maximally 300 mL) administered over 20 min immediately before con-
trast. Additionally, patients received oral sodium bicarbonate using
Nephrotransw, (Salmon, Basel, Switzerland; 500 mg NaHCO3/
capsule: 1 capsule/10 kg) with 1–2 dL of non-sparkling mineral water
(San Pellegrinow) at the start of the infusion.15 After contrast, patients
received additional 500 mL of non-sparkling mineral water that had to
be consumed within 6 h.
Additional oral fluid intake was encouraged in all groups. Additional
infusions were strongly discouraged and initiated only if clinically
indicated for other reasons. The rate of the study infusion was
reduced in patients who developed signs or symptoms of pulmonary
congestion. The administration of dopamine, mannitol, fenoldopam,
N-acetylcysteine (as it might reduce serum creatinine by interference
with the metabolism of creatinine), and theophylline during the
study period was strongly discouraged.11 The baseline serum creatin-
ine and cystatin C levels were measured from peripheral blood
samples obtained on the day preceding the contrast exposure. Post-
contrast serum creatinine and cystatin C levels were measured at
7 a.m. in the morning of Days 1 and 2 after the contrast procedure
in all patients.8,10,21
Endpoints
This trial was primarily designed to evaluate whether a regimen of a 24 h
infusion of sodium chloride 0.9% is superior to an infusion of 7 h sodium
bicarbonate at preventing contrast nephropathy (superiority analysis).
In addition, we evaluated whether a short-term regimen with sodium
bicarbonate is non-inferior to sodium bicarbonate during 7 h.
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Primary endpoint
The maximum change in eGFR within 48 h was calculated with the
highest creatinine level and using the abbreviated MDRD study
equation.16
Secondary endpoints
Development of CIN was defined as an increase of ≥25% or an in-
crease of ≥44 mmol/L in the baseline serum creatinine concentration
within 48 h.8,10,21 Further endpoints included post-contrast change in
serum cystatin C within 48 h, in-hospital morbidity and mortality,
90-day mortality, renal replacement therapy, and time to hospital
discharge.
All endpoints were assessed by physicians not involved in patient
care using all medical records pertaining to the patient. Follow-up
data were obtained by review of medical records and by contacting
patients at specified intervals by telephone interview performed by
two trained researchers. Primary care physicians were contacted in
the case of uncertainties regarding health status.
Statistical analysis
The trial was designed to enrol a total of 258 patients. The power cal-
culation was based on a hypothesized standard deviation of 20 mL/
min/1.73 m2 for individual reductions in the eGFR, a two-tailed
t-test, and an a level of 0.05.14,22 This study had a 90% power to
detect a difference in the change of the GFR of 10 mL/min/1.73 m2
between the 24 h sodium chloride group and the group with 7 h
sodium bicarbonate (superiority analysis). In addition, this study had
a 90% power for the non-inferiority analysis with an a level of 0.025
and a non-inferiority threshold of 10 mL/min/1.73 m2 for the difference
in the means of maximum change in glomerular filtration rate between
treatment arms C and B (non-inferiority analysis). Thus, non-inferiority
of Treatment C compared with Treatment B could be concluded if the
two-sided 95% confidence interval (CI) of the difference in these
means was larger than 210 mL/min/1.73 m2. Our study was sufficiently
powered to test each of the two main hypotheses separately at an a
level of 0.05, but not to maintain an overall a level of 0.05.
Continuous data are summarized by their mean (standard deviation)
or by their median (inter-quartile range) as appropriate. Categorical
data are presented as absolute values (percentages). Comparisons
between groups were performed using the t-test, ANOVA, Mann–
Whitney U-test, Fisher’s exact test, or Kruskal–Wallis test as appropri-
ate. Statistical analyses were performed with SPSS software (version
16.0).
Results
Between March 2005 and December 2009, we screened consecu-
tive hospitalized patients with renal insufficiency scheduled to
undergo intra-arterial or intravenous contrast procedures within
the next 24 h. Of 471 patients screened, a total of 273 patients
were randomized to receive one of the three prevention regimens
(Figure 1). Fifteen patients were excluded because they either did
not receive contrast medium or withdrew their consent after ran-
domization. This left 258 patients for final analysis.
Figure 1 Study flow diagram.
Contrast-induced nephropathy 2073
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics
Characteristic All patients
(n 5 258)
Standard 24 h sodium
chloride (Group A)
(n5 89)
7 h sodium bicarbonate
(Group B) (n5 87)
Short-term sodium
bicarbonate (Group C)
(n5 82)
Age, median (IQR), years 77 (69–81) 75 (70–82) 78 (70–82) 75 (65–81)
Male 166 (64) 55 (62) 57 (66) 54 (66)
BMI, mean (SD) 26.6 (5.3) 27.1 (5.8) 26.2 (5) 26.4 (5)
Renal function
Serum creatinine, median (IQR), mmol/L 137 (113–158) 141 (112–158) 141 (115–164) 128 (114–157)
eGFR, mean (SD) 43.6 (11.6) 43.0 (11.8) 43.1 (10.7) 44.8 (12.2)
Serum Cystatin C, median (IQR), mg/L 1.75 (1.47–2.1) 1.7 (1.49–2.09) 1.79 (1.51–2.16) 1.7 (1.42–2.05)
Protein/creatinine ratio (IQR), mg/mmola 16 (9–35) 14 (7–35) 17 (10–42) 17 (10–29)
Albumin/creatinine ratio (IQR), mg/mmola 3 (1–11) 2 (1–9) 4 (2–18) 3 (1–12)
Vital signs
Blood pressure, median (IQR), mmHg
Systolic 130 (120–147) 130 (120–145) 133 (120–150) 130 (115–147)
Diastolic 70 (60–80) 70 (60–80) 70 (60–80) 70 (60–80)
Heart rate, median (IQR), b.p.m. 70 (64–80) 70 (64–81) 70 (64–78) 69 (60–82)
History
Hypertension 213 (83) 72 (81) 78 (90) 63 (77)
Diabetes mellitus 96 (37) 30 (34) 34 (39) 32 (39)
Current smoker 40 (16) 13 (15) 13 (15) 14 (18)
Previous smoker 113 (45) 37 (43) 40 (46) 36 (46)
Dyslipidaemia 151 (59) 55 (63) 50 (58) 46 (56)
Coronary artery disease 150 (58) 54 (61) 53 (61) 43 (52)
Heart failure
No history of heart failure 144 (56) 47 (53) 53 (61) 44 (54)
History of heart failure, NYHA class I 34 (13) 15 (17) 10 (12) 9 (11)
History of heart failure, NYHA class II 80 (31) 27 (30) 24 (28) 29 (35)
Causes of renal dysfunction
Diabetic nephropathyb 16 (6) 8 (9) 6 (7) 2 (2)
Vascular nephropathyb 124 (48) 41 (46) 44 (51) 39 (48)
Combined diabetic and hypertensive
nephropathyb
60 (23) 20 (23) 18 (21) 22 (27)
Other causesc 38 (15) 12 (14) 14 (16) 12 (15)
Unknown 20 (8) 8 (9) 5 (6) 7 (9)
Medication
Angiotensin-converting enzyme inhibitors 112 (44) 39 (44) 39 (45) 34 (42)
Angiotensin receptor blockers 72 (28) 22 (25) 25 (29) 25 (31)
Diuretics 180 (70) 70 (80) 55 (63) 55 (67)
Metformin 18 (7) 8 (9) 3 (4) 7 (9)
Systemic glucocorticosteroids 31 (12) 10 (11) 12 (14) 9 (11)
Aspirin 143 (56) 50 (57) 44 (51) 49 (60)
NSAIDs 8 (3) 2 (2) 3 (3) 3 (4)
Radiocontrast proceduresd
Cardiac catheterizations 59 (23) 14 (16) 22 (25) 23 (28)
PCI 54 (21) 21 (24) 15 (17) 18 (22)
Computed tomography 117 (45) 40 (45) 39 (45) 38 (46)
Peripheral angiography 24 (9) 13 (15) 9 (10) 2 (2)
PTA 23 (9) 12 (14) 9 (10) 2 (2)
Continued
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Twenty-four hour sodium chloride infusion was administered in
89 patients (Group A), 87 patients received sodium bicarbonate
for 7 h (Group B), and 82 patients received the short-term
regimen of sodium bicarbonate (Group C). The baseline character-
istics were well matched among the groups (Table 1). The mean
age of the study population was 77 years and 64% were males.
The mean eGFR at baseline was 43.6+11.6 mL/min/1.73 m2. In
the majority of the patients, the cause of kidney dysfunction was
vascular nephropathy (48%) followed by the combination of vascu-
lar and diabetic nephropathy (23%). All patients received a non-
ionic contrast agent, the vast majority (88%) a low-osmolar
contrast agent. Eleven per cent (missing data in two patients)
received an iso-osmolar contrast agent. Six different products of
contrast medium were used: iopromide (590–770 mOsm/kg),
iomeprol (521–618 mOsm/kg), iopentol (810 mOsm/kg), iohexol
(640–844 mOsm/kg), iobitridol (695–915 mOsm/kg), and the iso-
osmolar iodixanol (290 mOsm/kg). Cardiac catheterization (23%),
percutaneous coronary intervention (21%) and computed tomog-
raphy (45%) were the main contrast procedures. Peripheral angi-
ography was conducted in 9% and percutaneous transluminal
angioplasty in 9% of the patients. Contrast volume was similar
among groups.
Safety
No patient experienced a serious adverse event related to the in-
fusion (death, intensive care unit admission). Also, no patient
required intravenous diuretics or nitrates due to pulmonary con-
gestion. Infusion rate was maintained constant in 97% of the
patients, and it was reduced in 7 patients in Group A and in 1
patient in Group C who developed symptoms of pulmonary con-
gestion. The uneven distribution of these cases across groups can
hardly be explained by chance alone (P ¼ 0.005 for differences
among groups and P ¼ 0.008 for Group A vs. Group B). Additional
volume was initiated in two patients due to other clinical indica-
tions (one in Group B and one in Group C).
Efficacy
Group A vs. Group B
The primary and secondary endpoints are displayed in Table 2. The
maximum change in eGFR within 48 h was significantly greater in
Group B when compared with Group A [mean difference 23.9
(95% CI, 26.8 to 21) mL/min/1.73 m2, P ¼ 0.009]. Similarly, the
maximum change in serum cystatin C was significantly greater in
Group B when compared with Group A [mean difference 0.15
(95% CI, 0.04–0.27) mg/L, P ¼ 0.01; Figure 2A]. The incidence of
CIN, defined as a maximum increase in serum creatinine of
≥25% from baseline, was significantly lower in Group A (n ¼ 1,
1%) vs. Group B (n ¼ 8, 9%, P ¼ 0.02; Table 2 and Figure 3].
Group B vs. Group C
The maximum change in eGFR within 48 h was similar in Groups B
and C [mean difference 1.3 (95% CI, 21.7–4.3] mL/min/1.73 m2,
P ¼ 0.39). Similarly, the maximum change in serum cystatin C
was similar in Groups B and C [mean difference 20.02 (95% CI,
20.12–0.08) mg/L, P ¼ 0.65; Figure 2A]. The incidence of CIN
was similar in Groups B and C (n ¼ 8, 10%, P ¼ 0.9; Table 2 and
Figure 3).
The mean eGFR before and after the contrast procedure in
each group is shown in Figure 2B. The effect modification of med-
ications interfering with the creatinine was tested in a multivari-
able regression analysis with dummy variables for the
consumption of medications and with interaction terms
between these variables and group membership. These inter-
action variables were far from reaching statistical significance,
and when eliminating them from the model, the group differences
were very similar to the ones obtained without adjustment for
medication intake.
Increases in serum pH and increases in bicarbonate concentra-
tion were significantly higher in patients who received a prevention
regimen containing sodium bicarbonate compared with sodium
chloride (Table 2).
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Table 1 Continued
Characteristic All patients
(n5 258)
Standard 24 h sodium
chloride (Group A)
(n5 89)
7 h sodium bicarbonate
(Group B) (n 5 87)
Short-term sodium
bicarbonate (Group C)
(n5 82)
Other procedures 4 (2) 1 (1) 2 (2) 1 (1)
Contrast volume, median (IQR), mL 100 (80–158) 100 (80–163) 100 (80–143) 100 (80–170)
Contrast product: iso-osmolare 29 (11) 8 (9) 11 (13) 10 (12)
To convert serum creatinine to mg/dL, divide by 88.4. Values are presented as n (%), unless otherwise indicated. Percentages may not equal 100 due to rounding. NYHA heart
failure class I and II indicate no symptoms and no limitation in ordinary physical activity and mild symptoms and slight limitation during ordinary activity, respectively. BMI, body
mass index, calculated as weight in kilograms divided by height in square metres; eGFR, estimated glomerular filtration rate mL/min/1.73 m2; IQR, inter-quartile range; NSAIDs,
non-steroidal anti-inflammatory drugs; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PTA, percutaneous transluminal angioplasty.
aAvailable in 113 patients.
bPatients with diabetic and/or hypertensive nephropathy could also have other nephropathy.
cIncluding vasculitis/glomerulonephritis, obstructive uropathy, interstitial nephritis, congenital nephropathy, functional single kidney, and drug toxicity.
dOne patient in Group A had angiography without PTA (0.4%).
eAll other patients received low-osmolar contrast medium, one patient received both.
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Table 2 Post-procedural outcomes—comparison between groups
Characteristic All patients
(n5 258)
Standard 24 h
sodium chloride
(Group A) (n 5 89)
7 h sodium
bicarbonate
(Group B)
(n5 87)
Short-term
sodium
bicarbonate
(Group C)
(n5 82)
P-value
A vs. B A vs. C B vs. C
Changes in renal function
Creatinine max.
change, median
(IQR), mmol/L
23 (215–10) 27 (219–5) 3 (212–20) 22 (213–9) 0.001 0.04 0.24
Creatinine max.
change, median
(IQR), %
22 (212–8) 26 (214–3) 2 (210–13) 21.5 (210–8) 0.001 0.04 0.22
eGFR max. change,
mean (SD)
1.8 (9.9) 4.0 (9.6) 0.1 (9.9) 1.4 (9.8) 0.009 0.08 0.39
Cystatin C max.
change, median
(IQR), mg/L
0 (20.13–0.14) 20.06 (20.26–0.08) 0.04 (20.08–0.22) 0.01 (20.07–0.17) ,0.001 0.002 0.29
Cystatin C max.
change, median
(IQR), %
0 (27.5–8.7) 24.5 (212.9–4.1) 2.2 (24.3–12.8) 0.5 (24.8–10.6) ,0.001 0.003 0.33
Changes in electrolytes and blood gases (from pre-contrast to 1-day post-contrast)
pH, mean (SD) 0.02 (0.05) 20.01 (0.04) 0.03 (0.06) 0.02 (0.04) ,0.001 ,0.001 0.09
Bicarbonate, mean
(SD), mmol/L
0.8 (3.1) 21.6 (2.3) 2.2 (2.7) 1.9 (2.7) ,0.001 ,0.001 0.49
Incidence of contrast induced nephropathy
Creatinine max.
increase
≥44 mmol/L
14 (5) 1 (1) 7 (8) 6 (7) 0.03 0.06 1.0
Creatinine max.
increase ≥25%
17 (7) 1 (1) 8 (9) 8 (10) 0.02 0.02 1.0
Comparison of means of changes in eGFR and maximum change in cystatin C after contrast procedure
Comparison Difference in
means (95%
confidence
interval)
P-valuea
Mean max. change
eGFR: Group B–
Group A
23.9 (26.8 to 21) 0.009b
Mean max. change
eGFR: Group C–
Group B
1.3 (21.7–4.3) 0.39c
Mean max. change
cystatin C, mg/L:
Group B–Group A
0.15 (0.04–0.27) 0.01
Mean max. change
cystatin C, mg/L:
Group C–Group B
20.02 (20.12–0.08) 0.65
Values are presented as n (%), unless otherwise specified. eGFR, estimated glomerular filtration rate, mL/min/1.73 m2; IQR, inter-quartile range. To convert serum creatinine to
mg/dL, divide by 88.4.
aAll P-values refer to the deviation of observed group differences from 0.
bBased on this finding, we conclude superiority of A over B, since all values of the 95% confidence interval of the difference in means are ,0.
cBased on this finding, we conclude non-inferiority of C compared with B, since all values of the 95% confidence interval of the difference in means are larger than the assumed
non-inferiority threshold of 210 mL/min/1.73 m2.
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Follow-up
In-hospital follow-up was complete in all patients; 90-day follow-up
was complete in 254 patients (98%). In-hospital morbidity and
mortality, time to hospital discharge, 90-day mortality, and renal
replacement therapy at 90 days did not differ significantly
between groups (Table 3).
Discussion
This study compared three different prevention procedures of CIN
in consecutive patients with renal dysfunction: the 24 h sodium
chloride 0.9% regimen, a 7 h regimen of sodium bicarbonate, and
a novel short-term (20 min) regimen of sodium bicarbonate. We
report four major findings: first, 24 h sodium chloride 0.9%
regimen is superior to the 7 h sodium bicarbonate regimen.
Secondly, a short-term regimen of sodium bicarbonate is non-
inferior to 7 h sodium bicarbonate. Thirdly, the safety of all regi-
mens was very high, even in patients with NYHA class I or II
heart failure. Fourthly, the incidence of CIN was quite low, docu-
menting the effectiveness of volume supplementation.4
These findings have major clinical implications and will help to
individualize treatment decisions in the prevention of CIN. If
maximal protection is required and it is feasible to initiate the in-
fusion 12 h before contrast, a 24 h sodium chloride 0.9%
regimen should be used. In all other patients, short-term sodium
bicarbonate may be the regimen of choice as it is very easy to
apply, even to outpatient procedures, and seems to have similar ef-
ficacy to the 7 h sodium bicarbonate regimen.
Our findings corroborate and extend previous data. A recent
meta-analysis of previous studies concluded that the effectiveness
of sodium bicarbonate treatment to prevent CIN in high-risk
patients remains uncertain. Earlier reports probably overesti-
mated the magnitude of any benefit, whereas larger, more
recent trials have had neutral results.23 However, early termin-
ation of the initial study, publication bias, small differences in
the concentration and overall amount of sodium bicarbonate
applied, the type of the contrast procedure, and patient selection
can only partly explain the discrepant findings.14,24–31 We hy-
pothesize that the biochemical properties of the contrast agent
used might affect the relative effectiveness of 24 h saline and
sodium bicarbonate. The vast majority of the patients in our
study received non-ionic low-osmolar contrast agents, the most
commonly used agent worldwide.24,27,30–32 For these contrast
agents, 24 h saline seems to be the most effective preventive
measure. Two recent studies applying iso-osmolar agents
showed contrary results.25,29 Briguori et al.25 used iso-osmolar
agents and found the combination of 7 h sodium bicarbonate
with high-dose N-acetylcysteine to be superior. Maioli et al.29
also used iso-osmolar agents and found similar effectiveness for
Figure 2 (A) Confidence intervals of differences between
groups in the means of maximal change in estimated glomerular
filtration rate and cystatin C after radiocontrast exposure. (B)
Means of estimated glomerular filtration rate before and after
the radiocontrast procedure in the three groups.
Figure 3 Incidence of contrast induced nephropathy defined as
an increase of ≥25% in the baseline serum creatinine concentra-
tion within 48 h in the three groups.
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24 h saline with low-dose N-acetylcysteine and 7 h bicarbonate
with low-dose N-acetylcysteine.
Our findings are in agreement with a recent meta-analysis, sug-
gesting a lack of a clear benefit of bicarbonate in patients undergo-
ing elective procedures compared with emergency procedures.32
Other possible mechanisms of bicarbonate may play a role, such
as buffering of subclinical acidosis-induced vasoconstriction, that
is typical of acute settings and that may amplify the vasoconstric-
tion induced by contrast itself.
Our data do not refute the original hypothesis generated by
Merten et al.,14 who postulated that alkalization using bicarbonate
might provide additional protection.24–30 We did not use equal
volumes in the study arms, but compared sodium bicarbonate
with 24 h sodium chloride 0.9% infusion, which is a well-accepted
regimen.20
This study has some important strengths. First, this is a multicen-
tre study and the population represents a real-life setting of hospi-
talized patients with renal insufficiency undergoing a contrast
procedure. Secondly, the regimens of volume supplementation
were compared without the interference of N-acetylcysteine, a
known confounder of eGFR.24,25 Thirdly, we included both
intra-arterial and intravenous procedures. Many previous studies
have exclusively enrolled patients undergoing intra-arterial con-
trast procedures. Arterio-arterial embolization to the kidneys is
an important potential contributor to post-procedural decline in
renal function and therefore challenges the evaluation of the pre-
vention of CIN. Furthermore, intravenous administration of con-
trast agents was postulated to be a risk factor for mortality
compared with intra-arterial procedures.33
This study has important limitations. First, we used a surrogate
marker as primary outcome. The study was not powered to evalu-
ate the impact of regimens of volume supplementation on hard
clinical outcomes such as renal replacement therapy and rehospi-
talization. However, previous data strongly support the concept
that post-procedural decrease in eGFR is associated with a
higher incidence of clinical events.3,33 Secondly, our study
documented the safety and efficacy of volume supplementation
also in patients with NYHA class I and II heart failure; however,
we cannot comment on the most effective preventive regimen in
patients with NYHA class III and IV heart failure, since such
patients were excluded from our study. As heart failure and
chronic kidney disease are closely linked and both increasing in
prevalence, further research in this area is desperately needed.34
Thirdly, in this study, true GFR was not measured, but estimated
on the basis of the MDRD formula. This estimation has limitations,
e.g. in elderly people.35 However, these limitations should not
affect the key findings of our study because of the randomized con-
trolled design. Potential alternative methods include the use of the
clearance of the contrast product as a measure of the real GFR.36
Fourthly, the MDRD formula has been validated on subjects
without intravenous infusions. This limitation is inherent to all
studies assessing volume supplementation.
In conclusion, volume supplementation with 24 h sodium chlor-
ide 0.9% is more effective than 7 h sodium bicarbonate in the pre-
vention of CIN and seems therefore to be the regimen of choice
whenever maximal protection is desired and logistics permits.
The short-term sodium bicarbonate regimen seems to be an at-
tractive alternative for all other patients, including those undergo-
ing outpatient procedures.
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